KRAS and familial pancreatic carcinoma: Oligonucleotide therapeutics can match this genomic profiling trend and target the molecules, including non-coding RNAs, which were not therapeutic targets previously, enabling the targeting of the KRAS gene, a critical trigger of pancreatic cancer progression.